Optical imaging probes have played a major role in detecting and 25 monitoring of a variety of diseases 1 . In particular, nonlinear optical imaging 26 probes, such as second harmonic generating (SHG) nanoprobes, hold great 27 promise as clinical contrast agents, as they can be imaged with little 28 background signal and unmatched long-term photostability 2 . As their chemical 29 composition often includes transition metals, the use of inorganic SHG 30 nanoprobes can raise long-term health concerns. Ideally, contrast agents for 31 biomedical applications should be degraded in vivo without any long-term 32 toxicological consequences to the organism. Here, we developed 33 biodegradable harmonophores (bioharmonophores) that consist of polymer-34 encapsulated, self-assembling peptides that generate a strong SHG signal. 35
tissue 5 . A key challenge for optical imaging probes and instrumentation, 48 particularly those aimed at eventual clinical applications, is to overcome the 49 limited depth penetration of excitation light, which often result in a low signal-50 to-noise ratio (SNR) 6 . The relatively poor photostability of most imaging probes 51 pose another challenge to provide reliable and sensitive imaging of tumors. 52
Previously, we introduced inorganic second harmonic generating (SHG) 53 nanocrystals, SHG nanoprobes 2 , as a new class of imaging probes that can be 54 used for in vivo imaging. Given that SHG imaging employs near infrared (NIR) 55 incident light for contrast generation, SHG nanoprobes can be utilized for deep 56 tissue imaging. Unlike commonly used fluorescent probes, SHG nanoprobes 57 neither bleach nor blink, and their signal does not saturate with increasing 58 illumination intensity, ensuring high probe sensitivity 7 . Since their signal profile 59 is very narrow, they can be imaged with high SNR by excluding the broad 60 emission of typical autofluorescence background 2 . Robust functionalization 61 allows targeting to a wide variety of cells and proteins of interest 8 , allowing 62 these imaging probes to be promising tools for both clinical and preclinical 63 imaging applications 9 . Despite these advantages, the chemical structure of 64 inorganic SHG nanoprobes makes them stable in the body, which may cause concerns for the long-term health of an organism that has been imaged with 66 these reporters. 67
To create a foundation for safe SHG nanoprobe-based clinical imaging, 68
we set out to generate a nanoprobe that consists of biodegradable materials, 69 capable of generating sufficient SHG signal that can be detected with high SNR. 70
Our efforts were guided by the observation that peptides with a variable number 71 of amino acid units can self-assemble into large, solid nanostructures of 72 different morphologies and symmetries 10 (Fig. 1a) . It has been previously 73
shown that such nanostructures can be ferroelectric and give nonlinear optical 74 contrast such as SHG 11, 12 (Fig. 1c) . 75
To render these nanostructures suitable for biological applications, we 76 evaluated methods for the encapsulation of self-assembling peptides in order 77 i) to hinder their macroscopic aggregation by confining their self-assembly in 78 nanodroplets without affecting their ability to generate a strong SHG signal, and 79 ii) to generate a nanoparticle that can be further functionalized without 80 influencing the peptide assembly. To this end, we subjected several peptides 81 that have been reported to self-assemble into complex nanostructures to the 82 emulsion-solvent evaporation method 13 , a widely-used procedure for the 83 fabrication of monolithic and core-shell nanoparticles (Fig. 1b, 
see Methods). 84
We identified three peptides with different self-assembling properties 85 (pentaalanine 14 , trileucine 15 , and triphenylalanine 16 ) that could generate 86 detectable SHG signal when encapsulated in the biodegradable polymer ( Fig.  87 1d and Supplementary Fig. 1 ). Transmission electron microscopy (TEM) 88 analysis of the predominantly spherical nanoparticles, hereinafter referred to as bioharmonophores, revealed a diameter ranging from 50-150 nm, which was 90 confirmed by dynamic light scattering (DLS) measurements ( Fig. 1e) . 91 SHG signal from bioharmonophores can stem from i) the bulk of the self-92 assembling peptides that form noncentrosymmetric crystalline structures or ii) 93 the surface of the bioharmonophores where there is no inversion symmetry. To 94 ascertain that the SHG signal originates from the crystalline peptide core, we 95 performed X-ray diffraction (XRD) analysis of bioharmonophores with different 96 peptide contents. In all cases, the peptides showed a high degree of internal 97 order with distinct diffraction patterns associated with their individual crystalline 98 phases and self-assembling behavior ( Supplementary Fig. 2a-d) . 99
Because bioharmonophores based on triphenylalanine (FFF) peptides 100 yielded the strongest SHG signal compared to pentaalanine and trileucine, we 101 subjected these bioharmonophores to detailed optical characterizations. The 102 SHG signal of FFF-based bioharmonophores was spectrally well-defined ( Fig.  103   2a) . Additionally, the SHG emission patterns of FFF-based bioharmonophores 104 displayed a broad opening: one seemingly isotropic, and the other one 105 displaying one lobe over 60° in the forward direction ( Fig. 2b) . These results 106 indicate that bioharmonophores emit SHG signal in multiple directions (unlike 107 the predominantly forward-directed SHG of large protein arrays) 7 , which 108 allowed illumination and collection of SHG signal using the same microscope 109 objective lens. Moreover, the presence of a single lobe demonstrates that the 110 observed SHG signal originates from the bulk of the bioharmonophores and not 111 from its surface, as described by Mie theory 17 . 112
Because SHG involves only virtual energy transitions, 113 bioharmonophores did not display blinking, remained stable over extended 114 periods of illumination, and their SHG signal intensity rose quadratically when 115 the laser intensity shone on them was linearly increased ( Supplementary Fig.  116 3a,b). The measured polarimetric diagrams (Fig 2c and Supplementary Fig.  117 3c-f) were consistent with the hypothesis that bioharmonophores have a self-118 assembling peptide core with a monoclinic (C2) symmetry. Indeed, the 119 experimental curves were well fitted with the analytical expression calculated 120 for this symmetry (see Supplementary Note 1 -Optical Characterization of 121 Bioharmonophores). Taken together, bioharmonophores have the same 122 photophysical advantages for biomedical imaging applications that have been 123 previously described for inorganic SHG nanoprobes 2 . 124
To gain insight into the parameters influencing the bioharmonophore 125 stability and signal intensity, we tested several reaction conditions to generate 126 bioharmonophores. Given that the SHG signal originating from 127 bioharmonophores is dependent on the amount of encapsulated peptide, we 128 first tested whether varying the FFF peptide concentration during production 129 would improve the SHG signal intensity of generated bioharmonophores ( Fig.  130 2d and Supplementary Fig. 4 ). We found that an amount of 15 mg FFF (i.e. 131 33wt%) peptide provided an optimal combination of intense SHG signal and 132 bioharmonophore stability. Interestingly, while an FFF peptide amount of 20 mg 133 (40wt%) increased the overall SHG signal, it also led to bioharmonophore 134 aggregation and decreased colloidal stability. Conversely, 10 mg (25wt%) FFF 135 peptide generated little SHG signal. 136
Because surfactant concentration plays a crucial role in emulsification of 137 chloroform droplets 13 , we reasoned that altering the surfactant concentration 138 during the preparation of bioharmonophores would have a profound effect on 139 their stability and signal strength ( Fig. 2e and Supplementary Fig. 5 ). 140
Bioharmonophores emulsified in an aqueous solution with 0.3% sodium 141 dodecyl sulfate (SDS) (i.e. 40wt% of dispersed phase) yielded stable 142 bioharmonophores with intense SHG signal, whereas compositions employing 143 0.1% SDS (18wt%) yielded aggregated nanoparticles. Increasing the SDS 144 concentration to 0.6% (57wt%) diminished the SHG signal intensity, suggesting 145 that the bioharmonophore size and hence the number of enclosed peptide 146 molecules within each bioharmonophore is influenced by the concentration of 147
surfactant. 148
Finally, we varied the polymer quantity that encapsulates and shields 149 peptides from environmental changes, and assessed its role in both SHG signal 150 intensity and nanoparticle morphology ( Fig. 2f and Supplementary Fig. 6 ). 151
We identified that an amount of 30 mg of poly(L-lactic acid) (PLLA) (66wt%) 152 resulted in an optimal combination of intense SHG signal and bioharmonophore 153 stability. Lower polymer amount of 10 mg (40 wt%) yielded weaker SHG signal, 154
whereas higher polymer amount (90 mg, 86 wt%) led to elongated 155 bioharmonophore morphologies. Taken together, we identified optimal 156 experimental conditions to generate bioharmonophores providing a high SNR 157
along with an excellent stability and size distribution for biological applications. 158
Clinical imaging probes that are biodegradable provide the significant 159 advantage of being able to be broken down in the body and removed after they 160 have served their function. To demonstrate that bioharmonophores are indeed 161 biodegradable, we utilized the highly effective serine protease, proteinase K, 162 which exhibits a broad cleavage specificity 18 . We incubated bioharmonophores 163 with a proteinase K concentration that is routinely used for dissolving tissue 164 structures 19 and probed the extent of degradation by monitoring the SHG signal 165 at different time intervals ( Fig. 3a) . We observed a decrease of SHG signal 166 within 2 hours of protease incubation. After 10 hours, the SHG signal 167 disappeared and the turbid bioharmonophore suspension became transparent 168 ( Fig. 3b and Supplementary Fig. 7) , indicating a successful biodegradation of 169 the bioharmonophore. 170
To evaluate bioharmonophore degradation under physiological 171 conditions ( Fig. 3c) , we functionalized bioharmonophores with Tat-derived cell 172 penetrating peptides 20 using bioorthogonal click chemistry, (Supplementary 173
Fig. 8), and incubated them with a model cancer cell line (see below) overnight. 174
Adherent cells were then detached by trypsinization, and centrifuged to remove 175 excess bioharmonophores that did not enter the cancer cells. Following this 176 procedure, cells were reseeded and fixed at specific time periods to monitor 177 bioharmonophores degradation (i.e. the intracellular presence of SHG signal 178 per cell) using nonlinear optical imaging. 30 hours after cell reseeding, a 179 pronounced decrease of intracellular SHG signal per cell was noticeable ( Fig.  180 3c). As bioharmonophores displayed long-term photostability even at low pH 181 values ( Supplementary Fig. 9 ), the drop of signal was not due to their potential 182 accumulation in acidic endolysosomal compartments over time. In order to 183
show that bioharmonophores can be degraded using intracellular proteolytic 184 degradation, we tested whether the bioharmonophores could be degraded 185 using a cell-free lysate system based on an established cell free degradation 186 assays 21 . We also observed reduced SHG signal, indicating that intracellular 187 enzymatic degradation of bioharmonophores might account for the signal loss 188 ( Fig. 3e and Supplementary Fig. 10) . Importantly, bioharmonophores did not exhibit any short-term toxicity in vitro and in vivo (Supplementary Fig. 11 ) and 190 did not induce protein aggregation 22 (Supplementary Fig. 12 (Fig. 4a) . By 3 days after the injection, the 203 resulting tumors spread to various locations in the body and were found next to 204 blood vessels, which likely support the tumors with nutrients 25 (Fig. 4b) . 205
To demonstrate the specificity and efficiency of bioharmonophores as 206 novel contrast agents that can accomplish resolution down to the single cell in 207 vivo, we targeted bioharmonophores to tumor sites by taking advantage of the 208 surface protein p32/gC1qR as a unique molecular marker for MDA-MB-435-209
DsRed cells 26 . To this end, we functionalized bioharmonophores with a p32 210 targeting peptide, injected them into the DoC of zebrafish embryos at 3 dpf, one 211 day after the embryos were injected with MDA-MB-435-DsRed cancer cells, 212 ( Fig. 4c) and assessed colocalization between cancer cells and 213 bioharmonophore signal at 5 dpf (see Supplementary Note 2 -Determining the fraction of bioharmonophore-labeled tumors in a zebrafish cancer model). 215
In the absence of tumors, functionalized bioharmonophores did not cause 216 clustering at the site of injection and were localized at different parts of injected 217 zebrafish embryos (Supplementary Fig. 13d-i) , indicating good biodistribution. 218
Without bioharmonophore injection, zebrafish as well as tumor sites did not 219 produce any SHG background signal (Supplementary Fig. 13a-c, 14a-c) with 220 the exception of minimal endogenous SHG signal localized at the zebrafish 221 tail 27 , which was excluded from assessing specificity of tumor targeting 222 (Supplementary Fig. 15 ). In the case of passive targeting, zebrafish injected 223 with PEG-coated bioharmonophores revealed limited tumor labeling 224 (Supplementary Fig. 14d-f) , stemming from leaky blood vessels and 225 enhanced permeability and retention effect (EPR) 28 . In contrast, we observed 226 an increased accumulation of p32 peptide-targeted bioharmonophores within 227 individual cancer cells at tumor sites throughout the zebrafish embryos ( Fig.  228   4c1-c4') , indicating that the tumor-labeling specificity and efficiency is highly 229 dependent on the p32 targeting peptide. While p32 peptide-targeted 230 bioharmonophores can extravasate to different tumor sites, not all the cancer 231 cells were labeled (Fig. 4c) . This observation is potentially due to limited 232 accessibility within densely packed solid tumors 29 and the continued 233 proliferation and metastasis of cancer cells between bioharmonophore 234 administration and imaging (see Supplementary Note 2 -Determining the 235 fraction of bioharmonophore-labeled tumors in a zebrafish cancer model). 236
In order to determine the extent of labeling of targeted 237 bioharmonophores in the xenograft zebrafish cancer model, we measured the 238 colocalization of cancer cells with bioharmonophores at each tumor site for non-injected zebrafish as well as for zebrafish that were injected with p32 peptide-240 targeted and PEG-coated bioharmonophores, respectively (see 241
Supplementary Note 2 -Determining the fraction of bioharmonophore-labeled 242 tumors in a zebrafish cancer model, Fig. 4c,d) . The number of tumors were not 243 significantly different between datasets (Supplementary Fig. 16) . The 244 zebrafish cancer model injected with p32 peptide-targeted bioharmonophores 245 had a significantly higher fraction of labeled tumors compared with non-injected 246 and PEG-coated bioharmonophores (Fig. 4d) due to our active targeting 247 strategy. Overall, these results demonstrate that bioharmonophores exhibit 248 high SNR and outstanding photostability for efficient labeling of individual 249 cancer cells at multiple tumor sites in vivo. 250
In summary, we introduced bioharmonophores as a novel class of 251 imaging probes that retain all the photophysical advantages of previously 252 Moreover, their unique ability to target single cells could be exploited for 263 detecting cancer stem cells, a subpopulation of cells responsible for tumorigenicity, invasion, and metastasis 32 . Once successfully identified, the 265 nonlinear signal of bioharmonophores could be used for light induced drug 266 delivery or photodynamic therapy 33 . By employing pulsed lasers in the infrared 267 wavelength range that permit deep tissue penetration, targeted 268 bioharmonophore signal could trigger highly localized cancer stem cell death 34 . 269
Finally, as the SHG signal intensity of bioharmonophore relies on the 270 unique self-assembly behavior of each peptide 35 , we anticipate that a screen 271 for alternative peptide sequences may yield even brighter bioharmonophores 272 that will potentially permit diagnosis with deep-tissue single-molecule detection 273 sensitivity. 274
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Figure Legends
The use of higher FFF peptide amount leads to aggregates (n=5). e, Influence 447 of SDS concentration (wt% of disperse phase) on SHG intensity of generated 448 bioharmonophores. The optimal condition (40 wt% SDS) with high 449 bioharmonophore stability and less aggregation is marked in green (n=5). f, 450
Influence of using different amounts of PLLA during bioharmonophore 451 production on the SHG intensity of the generated bioharmonophores. The 452 optimal condition (66 wt% PLLA) is marked in green (n=5 Quantification of the fraction of SHG-labeled tumors as the ratio of labeled 489 tumors to all tumors in a given zebrafish embryo after PEG-and p32 peptide-490 coated bioharmonophore injection, respectively. Each data point signifies one 491 zebrafish. Note that active targeting with p32-coated bioharmonophores 492 significantly increases the labelling efficiency (approx. 4-fold). Mean ± s.d. ****, 493 P < 0.0001, **, P = 0.0063, *, P = 0.0470 (non-parametric Kruskal-Wallis test 494 with Dunn's post hoc multiple comparison). N=12, pooled from 3 independent 495 experiments.
